Computer Modeling of Diabetes and Its Complications

Abstract Objectives The Mount Hood Challenge meetings provide a forum for computer modelers of diabetes to discuss and compare models, to assess predictions against data from clinical trials and other studies, and to identify key future developments in the field. This article reports the proceedings of the Fifth Mount Hood Challenge in 2010. Methods Eight modeling groups participated. Each group was given four modeling challenges to perform (in type 2 diabetes): to simulate a trial of a lipid-lowering intervention (The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus [ASPEN]), to simulate a trial of a blood glucose–lowering intervention (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation [ADVANCE]), to simulate a trial of a blood pressure–lowering intervention (Cardiovascular Risk in Diabetes [ACCORD]), and (optional) to simulate a second trial of blood glucose–lowering therapy (ACCORD). Model outcomes for each challenge were compared with the published findings of the respective trials. Results The results of the models varied from each other and, in some cases, from the published trial data in important ways. In general, the models performed well in terms of predicting the relative benefit of interventions, but performed less well in terms of quantifying the absolute risk of complications in patients with type 2 diabetes. Methodological challenges were highlighted including matching trial end-point definitions, the importance of assumptions concerning the progression of risk factors over time, and accurately matching the patient characteristics from each trial. Conclusions The Fifth Mount Hood Challenge allowed modelers, through systematic comparison and validation exercises, to identify important differences between models, address key methodological challenges, and discuss avenues of research to improve future diabetes models.

[1]  Deanna J. M. Isaman,et al.  A computer simulation model of diabetes progression, quality of life, and cost. , 2005, Diabetes care.

[2]  Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. , 1995, Kidney international.

[3]  R. Holman,et al.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.

[4]  Y. Hamamoto,et al.  Guidelines for computer modeling of diabetes and its complications. , 2004, Diabetes care.

[5]  S. Pocock,et al.  Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes , 2006, Diabetes Care.

[6]  Stephen W. Sorensen,et al.  The Cost-Effectiveness of Lifestyle Modification or Metformin in Preventing Type 2 Diabetes in Adults with Impaired Glucose Tolerance , 2005, Annals of Internal Medicine.

[7]  Volker Foos,et al.  Validation of the CORE Diabetes Model against epidemiological and clinical studies. , 2004, Current medical research and opinion.

[8]  R. Holman,et al.  Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23) , 1998, BMJ.

[9]  Volker Foos,et al.  The CORE Diabetes Model: Projecting Long-term Clinical Outcomes, Costs and Costeffectiveness of Interventions in Diabetes Mellitus (Types 1 and 2) to Support Clinical and Reimbursement Decision-making , 2004, Current medical research and opinion.

[10]  M. Vardi,et al.  Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype. , 2010, Pharmacogenomics.

[11]  Stephen J. Aldington,et al.  UKPDS 50: Risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis , 2001, Diabetologia.

[12]  A J Palmer,et al.  The Mt. Hood challenge: cross-testing two diabetes simulation models. , 2000, Diabetes research and clinical practice.

[13]  R. Holman,et al.  A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68) , 2004, Diabetologia.

[14]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[15]  Diederick Grobbee,et al.  Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. , 2008, The New England journal of medicine.

[16]  C. Byrne,et al.  Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed Type 2 diabetes: results from a United Kingdom study , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[17]  Michael E. Miller,et al.  Effects of intensive glucose lowering in type 2 diabetes. , 2008, The New England journal of medicine.

[18]  Rury R Holman,et al.  Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). , 2003, Kidney international.

[19]  Klas Bergenheim,et al.  Assessing the Relationship between Computational Speed and Precision , 2012, PharmacoEconomics.

[20]  S. Weinstein Fifty years of somatosensory research: from the Semmes-Weinstein monofilaments to the Weinstein Enhanced Sensory Test. , 1993, Journal of hand therapy : official journal of the American Society of Hand Therapists.

[21]  J. Peters,et al.  Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster) , 2006, Current medical research and opinion.

[22]  J. Peters,et al.  Evaluating the performance of the Framingham risk equations in a population with diabetes , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[23]  Ping Zhang,et al.  Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood challenge meeting. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[24]  M. Evans,et al.  Understanding the inter‐relationship between improved glycaemic control, hypoglycaemia and weight change within a long‐term economic model , 2010, Diabetes, obesity & metabolism.

[25]  Richard Stevens,et al.  Evaluation of methods for interval estimation of model outputs, with application to survival models , 2003 .

[26]  C. Chatfield Model uncertainty, data mining and statistical inference , 1995 .

[27]  N. Freemantle,et al.  Development and validation of the Economic Assessment of Glycemic Control and Long-Term Effects of diabetes (EAGLE) model. , 2006, Diabetes technology & therapeutics.

[28]  Irene M Stratton,et al.  Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. , 2004, Diabetes care.

[29]  D. Berry,et al.  Effect of screening and adjuvant therapy on mortality from breast cancer. , 2006, The New England journal of medicine.

[30]  Kevin A Peterson,et al.  Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus , 2011 .

[31]  Zara L Whitlock,et al.  Additional contributions by , 1979 .

[32]  K. Yeo,et al.  Predicting CHD risk in patients with diabetes mellitus , 2001, Diabetic medicine : a journal of the British Diabetic Association.

[33]  The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial. , 1995, Archives of ophthalmology.

[34]  The Effect of Intensive Diabetes Therapy on the Development and Progression of Neuropathy , 1995, Annals of Internal Medicine.

[35]  Vincent R. Gray Climate Change 2007: The Physical Science Basis Summary for Policymakers , 2007 .

[36]  David M Eddy,et al.  Archimedes: a trial-validated model of diabetes. , 2003, Diabetes care.

[37]  John H Fuller,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[38]  The Absence of a Glycemic Threshold for the Development of Long-Term Complications: The Perspective of the Diabetes Control and Complications Trial , 1996, Diabetes.

[39]  R. Holman,et al.  A Cardiovascular Risk Calculator for Type 2 Diabetes , 2005 .

[40]  Donghee Lee,et al.  Chronic disease modeling and simulation software , 2010, J. Biomed. Informatics.

[41]  R. Stevens,et al.  UKPDS 60: Risk of Stroke in Type 2 Diabetes Estimated by the UK Prospective Diabetes Study Risk Engine , 2002, Stroke.

[42]  Stephen W. Sorensen,et al.  Validation of the CDC-RTI diabetes cost-effectiveness model , 2009 .

[43]  Anke Richter,et al.  Optimal Allocation of Resources across Four Interventions for Type 2 Diabetes , 2002, Medical decision making : an international journal of the Society for Medical Decision Making.

[44]  J. Wylie-Rosett,et al.  Implementation of Treatment Protocols in the Diabetes Control and Complications Trial , 1995, Diabetes Care.

[45]  M I Mackness,et al.  Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes , 2002, Diabetic medicine : a journal of the British Diabetic Association.

[46]  R. Holman,et al.  The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). , 2001, Clinical science.

[47]  Anke Richter,et al.  Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. , 2002, JAMA.

[48]  David M Eddy,et al.  Validation of the archimedes diabetes model. , 2003, Diabetes care.

[49]  M. Willis,et al.  The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data. , 2000, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[50]  Stephen W. Sorensen,et al.  Screening for Type 2 Diabetes Mellitus: A Cost-Effectiveness Analysis , 2004, Annals of Internal Medicine.